Perspective Therapeutics paid its 4 named executives $7.7M in total in FY2025 (Dec). CEO Johan (Thijs) Spoor was paid $2.4M of that.
PayNo stock prices for these years
Pay of each named executive
Johan (Thijs) SpoorCEO and Director
| FY2025 (Dec) | ||||||
| FY2023 (Dec) |
2 years
Juan GrahamFormer Chief Financial Officer5
| FY2025 (Dec) |
1 year
Joel SendekChief Financial Officer4
| FY2025 (Dec) |
1 year
Markus Puhlmann, M.D.Chief Medical Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $4.7M. The CEO of Perspective Therapeutics was paid $2.4M, 49% below the median.
- 1Cogent Biosciences
- 2Kymera Therapeutics
- 3Immunome
- 4Oric Pharmaceuticals
- 5Kura Oncology
- 6Relay Therapeutics
- 7Lyell Immunopharma
- 8Olema Pharmaceuticals
- 9Tango Therapeutics
- 10Perspective TherapeuticsThis company
- 11ACELYRINNot disclosed
- 12ALX OncologyNot disclosed
- 13ArcellXNot disclosed
- 14Aura BiosciencesNot disclosed
- 15C4 TherapeuticsNot disclosed
- 16CG OncologyNot disclosed
- 17Caribou BiosciencesNot disclosed
- 18Day One BiopharmaceuticalsNot disclosed
- 19Fusion PharmaceuticalsNot disclosed
- 20Janux TherapeuticsNot disclosed
- 21MorphicNot disclosed
- 22Shattuck LabsNot disclosed
'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3cclipPath%20id='clip-path-2'%3e%3cpath%20id='Path_4394'%20d='M4.892,12.4c.758.192,1.629.412,2.67.6a27,27,0,0,0,5.02.426,18.387,18.387,0,0,0,4.07-.6,15.613,15.613,0,0,1,3.2-.6,2.179,2.179,0,0,1,1.861.814,3.668,3.668,0,0,1,.542,1.724c.058.524.058.872.35,1.086a3.609,3.609,0,0,0,1.821.31c.95.02,2.268-.02,3.12-.058s1.24-.077,1.531.1a1.153,1.153,0,0,1,.485.989,10.163,10.163,0,0,0-.136,1.3,2.4,2.4,0,0,0,.717,1.142,4.087,4.087,0,0,1,.872,1.222.844.844,0,0,1-.446,1.066,5.765,5.765,0,0,1-2.171.5,10.913,10.913,0,0,0-2.326.271c-.465.194-.426.581-.155.988s.776.833,1.028,1.3a1.084,1.084,0,0,1-.136,1.357,4.056,4.056,0,0,1-1.977.814c-.814.155-1.667.194-2.442.329a12.864,12.864,0,0,0-1.978.543c-.5.175-.814.291-.969.621a.85.85,0,0,0,.427,1.163,13.866,13.866,0,0,0,2.616.5c.872.175,1.453.484,1.55,1.047a13.544,13.544,0,0,1-.368,2.229,3.628,3.628,0,0,0,.523,2.267,1.967,1.967,0,0,0,1.589.755,8,8,0,0,0,2.364-.077,8.558,8.558,0,0,0,1.822-.736,1.836,1.836,0,0,1,1.861-.1,4.294,4.294,0,0,1,1.182,2.326c.194.872.155,1.569.891,2.015a14.815,14.815,0,0,0,3.664.93A14,14,0,0,1,41.4,42.242a9.687,9.687,0,0,1,1.736,1.229A24.91,24.91,0,1,0,4.892,12.4'%20transform='translate(-4.892%20-0.176)'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3c/defs%3e%3cg%20id='Group_3541'%20transform='translate(-0.094%20-0.128)'%3e%3cg%20id='Group_3282'%20transform='translate(0.094%2015.73)'%3e%3cg%20id='Group_3281'%20clip-path='url(%23clip-path)'%3e%3crect%20id='Rectangle_2848'%20width='33.837'%20height='20.982'%20transform='translate(-0.094%2033.75)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group_3284'%20transform='translate(3.563%200.128)'%3e%3cg%20id='Group_3283'%20clip-path='url(%23clip-path-2)'%3e%3crect%20id='Rectangle_2849'%20width='43.423'%20height='46.468'%20transform='translate(-0.12%2043.294)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23FEFEFE'%3e%3cpath%20d='M67.7444739,25%20L33.1043073,38.2478027%20L34.7958615,41.1131448%20L41.0490807,51.7151219%20L29.0986607,51.7151219%20L28,54.6065381%20L57.1428867,79%20L60.0675871,77.3612019%20L46.8800441,55.0029363%20L63.0277166,55.0032886%20L63.8216155,51.7151219%20L70,26.9178624%20L67.7444739,25%20Z%20M38,39.9222264%20L66,29%20L60.3908123,52%20L44.9725093,52%20L38,39.9222264%20Z%20M34,55%20L43.1090246,55%20L52,70%20L34,55%20Z'%20id='Fill-1-Copy'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.